Matthew Sykes
Stock Analyst at Goldman Sachs
(4.00)
# 514
Out of 5,179 analysts
197
Total ratings
52.38%
Success rate
9.73%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $9.07 | -44.87% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.32 | -30.56% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $19.48 | -66.63% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $33.72 | +33.45% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.28 | +86.92% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $44.53 | +7.79% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $13.13 | +29.47% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $102.08 | +56.74% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.19 | +39.08% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $83.90 | +48.99% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $7.41 | +88.93% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $181.52 | +32.22% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $16.78 | +54.95% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $159.16 | +6.81% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $84.61 | -33.81% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $57.09 | +40.13% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.26 | +19.05% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $182.65 | +4.02% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $3.48 | -49.71% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.86 | +48.60% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $30.01 | +23.29% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $163.85 | +52.58% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $3.58 | +570.39% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,232.04 | +5.52% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $5.93 | +102.36% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $473.36 | +35.20% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $110.24 | +31.53% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $39.07 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $9.07
Upside: -44.87%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.32
Upside: -30.56%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $19.48
Upside: -66.63%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $33.72
Upside: +33.45%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.28
Upside: +86.92%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $44.53
Upside: +7.79%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $13.13
Upside: +29.47%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $102.08
Upside: +56.74%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.19
Upside: +39.08%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $83.90
Upside: +48.99%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $7.41
Upside: +88.93%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $181.52
Upside: +32.22%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $16.78
Upside: +54.95%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $159.16
Upside: +6.81%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $84.61
Upside: -33.81%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $57.09
Upside: +40.13%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.26
Upside: +19.05%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $182.65
Upside: +4.02%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $3.48
Upside: -49.71%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.86
Upside: +48.60%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $30.01
Upside: +23.29%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $163.85
Upside: +52.58%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $3.58
Upside: +570.39%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,232.04
Upside: +5.52%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $5.93
Upside: +102.36%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $473.36
Upside: +35.20%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $110.24
Upside: +31.53%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $39.07
Upside: -